EF Hutton analyst Jason Kolbert initiated coverage of Kairos Pharma with a Buy rating and $9 price target Kairos is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics targeting immune suppression and drug resistance for cancer patients, the analyst tells investors in a research note. The firm says success in Phase 2 for the company’s lead candidate, KROS 101, is “transformative” for Kairos.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KAPA: